Clinical Trial of Yiqi Wenyang Jiedu Prescription in the Prevention and Treatment of Postoperative Metastasis and Recurrence of Gastric Cancer

• Status: Not yet recruiting
• Trial end date: 2024-07-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety of Yiqi Wenyang Jiedu prescription for postoperative gastric cancer.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jie Li

Criteria

Inclusion Criteria:

• The non-esophagogastric junction gastric cancer of stage II-III that met the diagnostic criteria, and no tumor recurrence and metastasis was determined by imaging;

• Within 6-8 months after radical gastrectomy for gastric cancer (R0), adjuvant chemotherapy of standard regimen (XELOX and SOX) has been completed for at least 6 cycles; ③ECOG score 0-2; ④18-75 years old, male or female; ⑤The expected survival time is ≥3 months; ⑥Voluntary participation in the study, signing informed consent, good compliance with follow-up.

Exclusion Criteria:

• Patients with other primary tumors;

• Gastric cancer patients were pathologically diagnosed as adenosquamous carcinoma, with lymphoid stromal carcinoma (medullary carcinoma), hepatoid adenocarcinoma, squamous cell carcinoma, signed-ring cell carcinoma, undifferentiated carcinoma, gastric neuroendocrine tumor, gastric mesenchymal tumor, gastric malignant lymphoma and other gastric malignancies

• Patients who had previously received preoperative neoadjuvant chemotherapy;

• Patients with past or current targeted drug therapy;

• Patients undergoing previous or ongoing gastric radiotherapy; ⑥ Patients with past or ongoing tumor immunotherapy;

• Mental patients;

• Patients with serious and uncontrolled organic diseases or infections, such as decompensated heart, lung and renal failure, which lead to intolerance of chemotherapy; ⑨ Patients who received clinical trials of small molecule drugs within 28 days or large molecule drugs within 3 months; ⑩ Patients who are known to be allergic or intolerant to the study drug.